Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention. Read more about Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Read more about A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography. Read more about Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography.
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Read more about Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Read more about Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.
Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Read more about Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review.
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Read more about Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Read more about Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Read more about Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Read more about Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
